Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.

10/08/2026, 8:43 PM • The Motley Fool

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.

10/06/2026, 9:10 AM • The Motley Fool

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight

The type 2 diabetes market is projected to experience steady growth through 2036, driven by rising global prevalence, obesity, and adoption of next-generation therapies including GLP-1 receptor agonists and SGLT2 inhibitors. Key emerging drugs from major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are expected to reshape the market landscape with improved glycemic control and weight management benefits.

10/05/2026, 1:00 PM • GlobeNewswire

Here Are My Top 4 Stocks to Buy in October

The article recommends four stocks for October investment: Viking Therapeutics for its unique monthly-dose GLP-1 weight loss drug candidate in a market expected to reach $200 billion by 2030; Alphabet for its dominant position in cloud computing AI services with 82% YoY growth and gaining market share; SoFi Technologies for strong revenue growth (40% YoY) and customer expansion despite recent setbacks; and MercadoLibre for its Amazon-like growth trajectory in Latin America with 50% YoY revenue growth despite margin pressures from free shipping initiatives.

10/05/2026, 8:24 AM • The Motley Fool

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?

Both Pfizer and Novo Nordisk face significant dividend safety concerns despite high yields. Novo Nordisk (4.7% yield) leads in GLP-1 drugs but has lost market share to Eli Lilly and lacks portfolio diversity, while Pfizer (6% yield) faces patent expirations and R&D challenges. However, Pfizer's broader product portfolio and acquisition strategy make it the relatively safer choice for dividend investors, despite both stocks carrying material risk.

10/04/2026, 5:15 PM • The Motley Fool

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).

10/02/2026, 8:13 PM • The Motley Fool

Novo provides update on the denecimig Biologics License Application (BLA) in the US

The FDA has extended its review of Novo Nordisk's denecimig BLA for haemophilia A treatment due to ongoing manufacturing facility remediation activities. No deficiencies were identified in clinical efficacy or safety data. Novo aims to launch denecimig in the US in H1 2027, pending regulatory approval. The delay does not impact Novo's 2026 financial outlook.

10/02/2026, 4:53 PM • GlobeNewswire

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.

10/02/2026, 12:15 PM • The Motley Fool

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?

Roche's weight loss drug candidate enicepatide has shown promising Phase 2 results with 22.5% mean weight loss over 48 weeks, potentially competing with Eli Lilly's Zepbound and Novo Nordisk's semaglutide. However, while enicepatide demonstrates competitive efficacy, Roche is unlikely to overtake the market leaders due to their deeper pipelines. Roche remains a solid investment opportunity with diversified healthcare products and consistent growth prospects.

09/30/2026, 10:24 AM • The Motley Fool

Novo Nordisk Gives Uninspiring Outlook

Novo Nordisk provided disappointing guidance to investors, forecasting a considerable slowdown in revenue growth. The company faces challenges including the patent cliff for its blockbuster drug Ozempic, which management acknowledged as a significant concern.

09/29/2026, 11:26 PM • The Motley Fool

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

Novo Nordisk has entered into an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP dual receptor agonist. The deal is valued at up to $2.6 billion, including a $300 million upfront payment, with Novo obtaining global rights excluding mainland China, Hong Kong, Macao, and Taiwan. The drug targets obesity, type 2 diabetes, and other metabolic diseases.

09/29/2026, 12:35 AM • GlobeNewswire

Here's Where Wall Street Analysts See Eli Lilly's Share Price Going

Eli Lilly's stock has underperformed the broader market in 2026 despite a strong 5-year run, trading at 40x earnings. Wall Street analysts are modestly bullish with an average price target of $1,325 (11% upside), with 25 of 30 analysts recommending buy. The expanding GLP-1 market, projected to reach $190 billion by 2045, and Lilly's strong patent protection through the late 2030s support a positive outlook despite competitive threats from Novo Nordisk.

09/26/2026, 12:32 PM • The Motley Fool

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

Eli Lilly discontinued development of a new GLP-1 weight-loss drug that failed to meet efficacy expectations. While GLP-1 drugs (Mounjaro, Zepbound, Foundayo) account for over 65% of the company's revenue, Eli Lilly is strategically preparing for future patent expirations by aggressively investing in its drug pipeline through acquisitions and in-house research, particularly in infectious diseases. The company's willingness to cut underperforming candidates and move quickly on acquisitions demonstrates strong long-term strategic positioning.

09/26/2026, 12:15 PM • The Motley Fool

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.

09/25/2026, 6:05 AM • The Motley Fool

Why Viking Therapeutics Stock Skyrocketed on Tuesday

Viking Therapeutics' stock surged 35.67% after announcing positive clinical trial results for its obesity drug VK2735. Participants lost 16-19% of body weight over 21 weeks and maintained up to 97% of weight loss with flexible dosing schedules. The drug showed strong tolerability with low discontinuation rates, positioning Viking as a potential challenger in the rapidly expanding obesity drug market projected to reach $150 billion by 2035.

09/23/2026, 12:04 AM • The Motley Fool